CARB-X is backing a Center for Global Development program, NeoTest, to accelerate the development and market uptake of neonatal sepsis diagnostics through a combined push-and-pull funding structure. The initiative targets the gap between prototype tools and real-world deployment for low-resource neonatal settings. NeoTest plans a ten-year, $60 million market-shaping facility designed to bridge development through milestone payments, implementation support, and advanced real-world uptake payments. The target product profile focuses on rapid tests that can rule in or rule out sepsis decisions at or near the point of care for newborns up to 59 days old. For biotech diagnostics companies, the structure is notable because it aims to reduce market uncertainty—aligning incentives so test makers can invest in scale, regulatory readiness, and clinical validation tied to adoption pathways.